시장보고서
상품코드
1287841

세계의 멀미 치료제 시장(2023-2027년)

Global Motion Sickness Drugs Market 2023-2027

발행일: | 리서치사: TechNavio | 페이지 정보: 영문 160 Pages | 배송안내 : 즉시배송


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

멀미 치료제 시장은 2022-2027년간 1억 3,649만 달러 확대될 것으로 예측되며, 예측 기간 동안 4.43%의 CAGR을 나타낼 것으로 예상됩니다. 멀미 치료제 시장에 대한 전반적인 분석, 시장 규모와 예측, 동향, 시장 성장 촉진요인 및 저해요인, 과제, 약 25개 벤더를 대상으로 한 벤더 분석 등의 정보를 전해드립니다.

현재의 시장 시나리오, 최신 동향 및 성장요인, 전체 시장 환경에 대한 최신 분석을 제공합니다. 이 시장을 주도하는 요인은 시판 의약품의 가용성, 다양한 형태의 멀미약의 가용성, 세계 여행 및 관광객 증가입니다.

이 보고서는 향후 몇 년 동안 멀미 치료제 시장 성장을 견인할 주요 요인 중 하나로 메스꺼움을 유발하는 정보 기술의 출현을 꼽았습니다. 또한, 온라인 채널의 보급 증가와 심신증에 대한 조사 증가는 이 시장에서 큰 수요를 창출할 것으로 보입니다.

목차

제1장 주요 요약

  • 시장 개요

제2장 시장 구도

  • 시장 생태계

제3장 시장 규모

  • 시장의 정의
  • 시장별 부문 분석
  • 시장 규모(2022년)
  • 시장 전망(2022-2027년)

제4장 시장 규모 실적

  • 세계의 멀미 치료제 시장(2017-2021년)
  • 제품별 부문 분석(2017-2021년)
  • 유통 채널별 부문 분석(2017-2021년)
  • 지역별 부문 분석(2017-2021년)
  • 국가별 부문 분석(2017-2021년)

제5장 Five Forces 분석

  • Five Forces 요약
  • 바이어의 교섭력
  • 공급 기업의 교섭력
  • 신규 진출업체의 위협
  • 대체품의 위협
  • 경쟁 위협
  • 시장 현황

제6장 시장 세분화 : 제품별

  • 시장 부문
  • 비교 : 제품별
  • 항히스타민제 : 시장 규모와 예측(2022-2027년)
  • 항콜린제 : 시장 규모와 예측(2022-2027년)
  • 시장 기회 : 제품별

제7장 시장 세분화 : 유통 채널별

  • 시장 부문
  • 비교 : 유통 채널별
  • 오프라인 : 시장 규모와 예측(2022-2027년)
  • 온라인 : 시장 규모와 예측(2022-2027년)
  • 시장 기회 : 유통 채널별

제8장 고객 상황

  • 고객 상황 개요

제9장 지역별 상황

  • 지역별 세분화
  • 지역별 비교
  • 북미 : 시장 규모와 예측(2022-2027년)
  • 유럽 : 시장 규모와 예측(2022-2027년)
  • 아시아 : 시장 규모와 예측(2022-2027년)
  • 세계 기타 지역 : 시장 규모와 예측(2022-2027년)
  • 미국 : 시장 규모와 예측(2022-2027년)
  • 캐나다 : 시장 규모와 예측(2022-2027년)
  • 영국 : 시장 규모와 예측(2022-2027년)
  • 중국 : 시장 규모와 예측(2022-2027년)
  • 독일 : 시장 규모와 예측(2022-2027년)
  • 지역 상황별 시장 기회

제10장 성장 촉진요인, 과제 및 동향

  • 시장 성장 촉진요인
  • 시장이 해결해야 할 과제
  • 성장 촉진요인과 과제의 영향
  • 시장 동향

제11장 벤더 구도

  • 개요
  • 벤더 구도
  • 혼란 상황
  • 업계 리스크

제12장 벤더 분석

  • 대상 벤더
  • 벤더의 시장 포지셔닝
  • Abbott Laboratories
  • Amneal Pharmaceuticals Inc.
  • Baxter International Inc.
  • CVS Health Corp.
  • GlaxoSmithKline Plc
  • Lupin Ltd.
  • Myungmoon Pharm Co. Ltd.
  • Novartis AG
  • Perrigo Co. Plc
  • Prestige Consumer Healthcare Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Tivic Health Systems Inc.
  • Viatris Inc.
  • WellSpring Pharmaceutical Corp.
  • Zydus Lifesciences Ltd.

제13장 부록

LSH 23.06.28

The motion sickness drugs market is forecasted to grow by USD 136.49 mn during 2022-2027, accelerating at a CAGR of 4.43% during the forecast period. The report on the motion sickness drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the availability of over-the-counter (otc) drugs, availability of motion sickness drugs in multiple dosage forms, and growing travel and tourism worldwide.

Technavio's motion sickness drugs market is segmented as below:

By Product

  • Antihistamines
  • Anticholinergics

By Distribution Channel

  • Offline
  • Online

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the advent of nauseogenic information technology as one of the prime reasons driving the motion sickness drugs market growth during the next few years. Also, increased penetration of online channels and growing research on psychosomatic disorders will lead to sizable demand in the market.

The report on the motion sickness drugs market covers the following areas:

  • Motion sickness drugs market sizing
  • Motion sickness drugs market forecast
  • Motion sickness drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading motion sickness drugs market vendors that include Abbott Laboratories, Amneal Pharmaceuticals Inc., Baxter International Inc., CVS Health Corp., DM Pharma Marketing Pvt. Ltd., GlaxoSmithKline Plc, Hylands, Lupin Ltd., Merck KGaA, Myungmoon Pharm Co. Ltd., Novartis AG, Perrigo Co. Plc, Prestige Consumer Healthcare Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Tivic Health Systems Inc., Viatris Inc., WellSpring Pharmaceutical Corp., Zenomed Healthcare Pvt. Ltd., and Zydus Lifesciences Ltd.. Also, the motion sickness drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
  • Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Exhibit 07: Executive Summary - Chart on Incremental Growth
  • Exhibit 08: Executive Summary - Data Table on Incremental Growth
  • Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 13: Market segments
  • 3.3 Market size 2022
  • 3.4 Market outlook: Forecast for 2022-2027
  • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

  • 4.1 Global motion sickness drugs market 2017 - 2021
  • Exhibit 18: Historic Market Size - Data Table on global motion sickness drugs market 2017 - 2021 ($ million)
  • 4.2 Product Segment Analysis 2017 - 2021
  • Exhibit 19: Historic Market Size - Product Segment 2017 - 2021 ($ million)
  • 4.3 Distribution Channel Segment Analysis 2017 - 2021
  • Exhibit 20: Historic Market Size - Distribution Channel Segment 2017 - 2021 ($ million)
  • 4.4 Geography Segment Analysis 2017 - 2021
  • Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • 4.5 Country Segment Analysis 2017 - 2021
  • Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
  • 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Product

  • 6.1 Market segments
  • Exhibit 30: Chart on Product - Market share 2022-2027 (%)
  • Exhibit 31: Data Table on Product - Market share 2022-2027 (%)
  • 6.2 Comparison by Product
  • Exhibit 32: Chart on Comparison by Product
  • Exhibit 33: Data Table on Comparison by Product
  • 6.3 Antihistamines - Market size and forecast 2022-2027
  • Exhibit 34: Chart on Antihistamines - Market size and forecast 2022-2027 ($ million)
  • Exhibit 35: Data Table on Antihistamines - Market size and forecast 2022-2027 ($ million)
  • Exhibit 36: Chart on Antihistamines - Year-over-year growth 2022-2027 (%)
  • Exhibit 37: Data Table on Antihistamines - Year-over-year growth 2022-2027 (%)
  • 6.4 Anticholinergics - Market size and forecast 2022-2027
  • Exhibit 38: Chart on Anticholinergics - Market size and forecast 2022-2027 ($ million)
  • Exhibit 39: Data Table on Anticholinergics - Market size and forecast 2022-2027 ($ million)
  • Exhibit 40: Chart on Anticholinergics - Year-over-year growth 2022-2027 (%)
  • Exhibit 41: Data Table on Anticholinergics - Year-over-year growth 2022-2027 (%)
  • 6.5 Market opportunity by Product
  • Exhibit 42: Market opportunity by Product ($ million)
  • Exhibit 43: Data Table on Market opportunity by Product ($ million)

7 Market Segmentation by Distribution Channel

  • 7.1 Market segments
  • Exhibit 44: Chart on Distribution Channel - Market share 2022-2027 (%)
  • Exhibit 45: Data Table on Distribution Channel - Market share 2022-2027 (%)
  • 7.2 Comparison by Distribution Channel
  • Exhibit 46: Chart on Comparison by Distribution Channel
  • Exhibit 47: Data Table on Comparison by Distribution Channel
  • 7.3 Offline - Market size and forecast 2022-2027
  • Exhibit 48: Chart on Offline - Market size and forecast 2022-2027 ($ million)
  • Exhibit 49: Data Table on Offline - Market size and forecast 2022-2027 ($ million)
  • Exhibit 50: Chart on Offline - Year-over-year growth 2022-2027 (%)
  • Exhibit 51: Data Table on Offline - Year-over-year growth 2022-2027 (%)
  • 7.4 Online - Market size and forecast 2022-2027
  • Exhibit 52: Chart on Online - Market size and forecast 2022-2027 ($ million)
  • Exhibit 53: Data Table on Online - Market size and forecast 2022-2027 ($ million)
  • Exhibit 54: Chart on Online - Year-over-year growth 2022-2027 (%)
  • Exhibit 55: Data Table on Online - Year-over-year growth 2022-2027 (%)
  • 7.5 Market opportunity by Distribution Channel
  • Exhibit 56: Market opportunity by Distribution Channel ($ million)
  • Exhibit 57: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview
  • Exhibit 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • Exhibit 59: Chart on Market share By Geographical Landscape 2022-2027 (%)
  • Exhibit 60: Data Table on Market share By Geographical Landscape 2022-2027 (%)
  • 9.2 Geographic comparison
  • Exhibit 61: Chart on Geographic comparison
  • Exhibit 62: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2022-2027
  • Exhibit 63: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 64: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 65: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibit 66: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • 9.4 Europe - Market size and forecast 2022-2027
  • Exhibit 67: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 68: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 69: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibit 70: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • 9.5 Asia - Market size and forecast 2022-2027
  • Exhibit 71: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 72: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 73: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibit 74: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
  • Exhibit 75: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 76: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 77: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibit 78: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • 9.7 US - Market size and forecast 2022-2027
  • Exhibit 79: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 80: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 81: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibit 82: Data Table on US - Year-over-year growth 2022-2027 (%)
  • 9.8 Canada - Market size and forecast 2022-2027
  • Exhibit 83: Chart on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 84: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 85: Chart on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibit 86: Data Table on Canada - Year-over-year growth 2022-2027 (%)
  • 9.9 UK - Market size and forecast 2022-2027
  • Exhibit 87: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 88: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 89: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibit 90: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • 9.10 China - Market size and forecast 2022-2027
  • Exhibit 91: Chart on China - Market size and forecast 2022-2027 ($ million)
  • Exhibit 92: Data Table on China - Market size and forecast 2022-2027 ($ million)
  • Exhibit 93: Chart on China - Year-over-year growth 2022-2027 (%)
  • Exhibit 94: Data Table on China - Year-over-year growth 2022-2027 (%)
  • 9.11 Germany - Market size and forecast 2022-2027
  • Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • 9.12 Market opportunity By Geographical Landscape
  • Exhibit 99: Market opportunity By Geographical Landscape ($ million)
  • Exhibit 100: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • Exhibit 101: Impact of drivers and challenges in 2022 and 2027
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • Exhibit 102: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
  • Exhibit 103: Overview on factors of disruption
  • 11.4 Industry risks
  • Exhibit 104: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
  • Exhibit 105: Vendors covered
  • 12.2 Market positioning of vendors
  • Exhibit 106: Matrix on vendor position and classification
  • 12.3 Abbott Laboratories
  • Exhibit 107: Abbott Laboratories - Overview
  • Exhibit 108: Abbott Laboratories - Business segments
  • Exhibit 109: Abbott Laboratories - Key news
  • Exhibit 110: Abbott Laboratories - Key offerings
  • Exhibit 111: Abbott Laboratories - Segment focus
  • 12.4 Amneal Pharmaceuticals Inc.
  • Exhibit 112: Amneal Pharmaceuticals Inc. - Overview
  • Exhibit 113: Amneal Pharmaceuticals Inc. - Business segments
  • Exhibit 114: Amneal Pharmaceuticals Inc. - Key news
  • Exhibit 115: Amneal Pharmaceuticals Inc. - Key offerings
  • Exhibit 116: Amneal Pharmaceuticals Inc. - Segment focus
  • 12.5 Baxter International Inc.
  • Exhibit 117: Baxter International Inc. - Overview
  • Exhibit 118: Baxter International Inc. - Business segments
  • Exhibit 119: Baxter International Inc. - Key news
  • Exhibit 120: Baxter International Inc. - Key offerings
  • Exhibit 121: Baxter International Inc. - Segment focus
  • 12.6 CVS Health Corp.
  • Exhibit 122: CVS Health Corp. - Overview
  • Exhibit 123: CVS Health Corp. - Business segments
  • Exhibit 124: CVS Health Corp. - Key news
  • Exhibit 125: CVS Health Corp. - Key offerings
  • Exhibit 126: CVS Health Corp. - Segment focus
  • 12.7 GlaxoSmithKline Plc
  • Exhibit 127: GlaxoSmithKline Plc - Overview
  • Exhibit 128: GlaxoSmithKline Plc - Business segments
  • Exhibit 129: GlaxoSmithKline Plc - Key news
  • Exhibit 130: GlaxoSmithKline Plc - Key offerings
  • Exhibit 131: GlaxoSmithKline Plc - Segment focus
  • 12.8 Lupin Ltd.
  • Exhibit 132: Lupin Ltd. - Overview
  • Exhibit 133: Lupin Ltd. - Product / Service
  • Exhibit 134: Lupin Ltd. - Key news
  • Exhibit 135: Lupin Ltd. - Key offerings
  • 12.9 Myungmoon Pharm Co. Ltd.
  • Exhibit 136: Myungmoon Pharm Co. Ltd. - Overview
  • Exhibit 137: Myungmoon Pharm Co. Ltd. - Product / Service
  • Exhibit 138: Myungmoon Pharm Co. Ltd. - Key offerings
  • 12.10 Novartis AG
  • Exhibit 139: Novartis AG - Overview
  • Exhibit 140: Novartis AG - Business segments
  • Exhibit 141: Novartis AG - Key offerings
  • Exhibit 142: Novartis AG - Segment focus
  • 12.11 Perrigo Co. Plc
  • Exhibit 143: Perrigo Co. Plc - Overview
  • Exhibit 144: Perrigo Co. Plc - Business segments
  • Exhibit 145: Perrigo Co. Plc - Key news
  • Exhibit 146: Perrigo Co. Plc - Key offerings
  • Exhibit 147: Perrigo Co. Plc - Segment focus
  • 12.12 Prestige Consumer Healthcare Inc.
  • Exhibit 148: Prestige Consumer Healthcare Inc. - Overview
  • Exhibit 149: Prestige Consumer Healthcare Inc. - Business segments
  • Exhibit 150: Prestige Consumer Healthcare Inc. - Key offerings
  • Exhibit 151: Prestige Consumer Healthcare Inc. - Segment focus
  • 12.13 Sun Pharmaceutical Industries Ltd.
  • Exhibit 152: Sun Pharmaceutical Industries Ltd. - Overview
  • Exhibit 153: Sun Pharmaceutical Industries Ltd. - Product / Service
  • Exhibit 154: Sun Pharmaceutical Industries Ltd. - Key offerings
  • 12.14 Tivic Health Systems Inc.
  • Exhibit 155: Tivic Health Systems Inc. - Overview
  • Exhibit 156: Tivic Health Systems Inc. - Product / Service
  • Exhibit 157: Tivic Health Systems Inc. - Key offerings
  • 12.15 Viatris Inc.
  • Exhibit 158: Viatris Inc. - Overview
  • Exhibit 159: Viatris Inc. - Business segments
  • Exhibit 160: Viatris Inc. - Key news
  • Exhibit 161: Viatris Inc. - Key offerings
  • Exhibit 162: Viatris Inc. - Segment focus
  • 12.16 WellSpring Pharmaceutical Corp.
  • Exhibit 163: WellSpring Pharmaceutical Corp. - Overview
  • Exhibit 164: WellSpring Pharmaceutical Corp. - Product / Service
  • Exhibit 165: WellSpring Pharmaceutical Corp. - Key offerings
  • 12.17 Zydus Lifesciences Ltd.
  • Exhibit 166: Zydus Lifesciences Ltd. - Overview
  • Exhibit 167: Zydus Lifesciences Ltd. - Business segments
  • Exhibit 168: Zydus Lifesciences Ltd. - Key offerings
  • Exhibit 169: Zydus Lifesciences Ltd. - Segment focus

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • Exhibit 170: Inclusions checklist
  • Exhibit 171: Exclusions checklist
  • 13.3 Currency conversion rates for US$
  • Exhibit 172: Currency conversion rates for US$
  • 13.4 Research methodology
  • Exhibit 173: Research methodology
  • Exhibit 174: Validation techniques employed for market sizing
  • Exhibit 175: Information sources
  • 13.5 List of abbreviations
  • Exhibit 176: List of abbreviations
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제